Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00939523 · OUTCOME

Change in Tumor Volume

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy · Source last updated 2020-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Percent volume
Interval / dispersion
Full Range
Time frame
baseline and at 6 months

What was measured

Tumor volume will be assessed on MRI at 6 months on therapy and compared to baseline MRI.

Analysis population: Note: 1 subject was withdrawn after 6 weeks of lapatinib therapy and therefore not included in analysis. A 2nd subject was not included in this analysis as the drug was given on compassionate basis to prevent recurrence of her tumor. She had a negative baseline MRI and maintained a negative MRI at study end.

Groups in this outcome

Lapatinib

All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study. Lapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lapatinib7

Reported measurements

Source class 1
Values in Percent volume · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Lapatinib10Not reported-41.4318Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -41.4
        upper Limit
        318
        value
        10
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    units
    Participants
description
Tumor volume will be assessed on MRI at 6 months on therapy and compared to baseline MRI.
dispersion Type
Full Range
groups
  1. description
    All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study. Lapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.
    id
    OG000
    title
    Lapatinib
param Type
MEDIAN
population Description
Note: 1 subject was withdrawn after 6 weeks of lapatinib therapy and therefore not included in analysis. A 2nd subject was not included in this analysis as the drug was given on compassionate basis to prevent recurrence of her tumor. She had a negative baseline MRI and maintained a negative MRI at study end.
reporting Status
POSTED
time Frame
baseline and at 6 months
title
Change in Tumor Volume
type
PRIMARY
unit Of Measure
Percent volume

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice